Summary
Results from the EVEREST trial indicated that in patients with acute decompensated heart failure, tolvaptan, an oral nonpeptide vasopressin V2-receptor blocker, did not reduce mortality or hospitalizations but did provide modest symptomatic relief.
- Cardiology Clinical Trials
- Heart Failure
- © 2007 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.